Cell therapy for prenatal repair of myelomeningocele: A systematic review
- PMID: 32624428
- DOI: 10.1016/j.retram.2020.04.004
Cell therapy for prenatal repair of myelomeningocele: A systematic review
Abstract
Myelomeningocele (MMC) is a spinal cord congenital defect that leads to paraplegia, bladder incontinence and bowel dysfunction. A randomized human trial demonstrated that in utero surgical repair of the MMC defect improves lower limb motor function. However, functional recovery remains incomplete. Stem cell therapy has recently generated great interest in the field of prenatal repair of MMC. In this systematic review we attempt to provide an overview of the current application of stem cells in different animal models of MMC. Publications were retrieved from PubMed and Cochrane Library databases. This process yielded twenty-two studies for inclusion in this review, experimenting five different types of stem cells: human embryonic stem cells, neural stem cells, induced pluripotent stem cells, human amniotic fluid stem cells, and mesenchymal stem cells (MSCs). Rodents and ovine were the two major species used for animal model studies. The source, the aims, and the main results were analyzed. Stem cell therapy appears to be a promising candidate for prenatal repair of MMC, especially MSCs. Further explorations in ovine and rodent models, reporting clinical and functional results, are necessary before an application in humans.
Keywords: Cell therapy; Fetal surgery; Myelomeningocele; Sheep; Spina Bifida; Stem cell.
Copyright © 2020 Elsevier Masson SAS. All rights reserved.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
